| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight Heparins
|
Geno J. Merli
|
|
2001
|
11 |
3 |
p. 247-259
13 p.
|
artikel
|
| 2 |
Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight Heparins
|
Merli, Geno J.
|
|
2001
|
11 |
3 |
p. 247-259
|
artikel
|
| 3 |
Augmentation of In-Vitro Clot Dissolution by Low Frequency High-Intensity Ultrasound Combined with Antiplatelet and Antithrombotic Drugs
|
Shaul Atar
|
|
2001
|
11 |
3 |
p. 223-228
6 p.
|
artikel
|
| 4 |
Augmentation of In-Vitro Clot Dissolution by Low Frequency High-Intensity Ultrasound Combined with Antiplatelet and Antithrombotic Drugs
|
Atar, Shaul
|
|
2001
|
11 |
3 |
p. 223-228
|
artikel
|
| 5 |
Elevation in Serum Troponin I Predicts the Benefit of Tirofiban
|
James L. Januzzi
|
|
2001
|
11 |
3 |
p. 211-215
5 p.
|
artikel
|
| 6 |
Elevation in Serum Troponin I Predicts the Benefit of Tirofiban
|
Januzzi, James L.
|
|
2001
|
11 |
3 |
p. 211-215
|
artikel
|
| 7 |
Low Molecular Weight Heparin Therapy for Percutaneous Coronary Intervention: A Practice in Evolution
|
Joseph K. Choo
|
|
2001
|
11 |
3 |
p. 235-246
12 p.
|
artikel
|
| 8 |
Low Molecular Weight Heparin Therapy for Percutaneous Coronary Intervention: A Practice in Evolution
|
Choo, Joseph K.
|
|
2001
|
11 |
3 |
p. 235-246
|
artikel
|
| 9 |
Noninvasive Transthoracic Low Frequency Ultrasound Augments Thrombolysis in a Canine Model of Acute Myocardial Infarction Evaluation of the Extent of ST-Segment Resolution
|
Yochai Birnbaum
|
|
2001
|
11 |
3 |
p. 229-234
6 p.
|
artikel
|
| 10 |
Noninvasive Transthoracic Low Frequency Ultrasound Augments Thrombolysis in a Canine Model of Acute Myocardial Infarction – Evaluation of the Extent of ST-Segment Resolution
|
Birnbaum, Yochai
|
|
2001
|
11 |
3 |
p. 229-234
|
artikel
|
| 11 |
Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease
|
Kurt Huber
|
|
2001
|
11 |
3 |
p. 183-193
11 p.
|
artikel
|
| 12 |
Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease
|
Huber, Kurt
|
|
2001
|
11 |
3 |
p. 183-193
|
artikel
|
| 13 |
Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents
|
Kurt Huber
|
|
2001
|
11 |
3 |
p. 195-202
8 p.
|
artikel
|
| 14 |
Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents
|
Huber, Kurt
|
|
2001
|
11 |
3 |
p. 195-202
|
artikel
|
| 15 |
Relationship Between the Heparin Management Test and the HemoTec Activated Clotting Time in Patients Undergoing Percutaneous Coronary Intervention
|
Sotirios Tsimikas
|
|
2001
|
11 |
3 |
p. 217-221
5 p.
|
artikel
|
| 16 |
Relationship Between the Heparin Management Test and the HemoTec Activated Clotting Time in Patients Undergoing Percutaneous Coronary Intervention
|
Tsimikas, Sotirios
|
|
2001
|
11 |
3 |
p. 217-221
|
artikel
|
| 17 |
Short-Term Comparative Outcomes Associated with the Use of GP IIbIIIa Antagonists in Patients Undergoing Coronary Intervention
|
Carey Kimmelstiel
|
|
2001
|
11 |
3 |
p. 203-209
7 p.
|
artikel
|
| 18 |
Short-Term Comparative Outcomes Associated with the Use of GP IIb/IIIa Antagonists in Patients Undergoing Coronary Intervention
|
Kimmelstiel, Carey
|
|
2001
|
11 |
3 |
p. 203-209
|
artikel
|
| 19 |
Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS): The New Thinking
|
Jingxuan Liu
|
|
2001
|
11 |
3 |
p. 261-272
12 p.
|
artikel
|
| 20 |
Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS): The New Thinking
|
Liu, Jingxuan
|
|
2001
|
11 |
3 |
p. 261-272
|
artikel
|
Tijdschrift beschrijving